{"id":"W4313553529","doi":"10.1200/jco.22.02331","title":"Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"American Society of Clinical Oncology","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Trastuzumab; Ramucirumab; Oncology; Ipilimumab; Cancer; Targeted therapy; Esophageal cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Immunotherapy; Progressive disease; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003838767,0.0003787877,0.006707803,0.0003410848,0.00005585404,0.00001576606,0.0002889523,0.0005803097,0.0001310719],"category_scores_gemma":[0.001291988,0.0002391584,0.00206571,0.0002724146,0.0001549074,0.00007304627,0.00006137466,0.001109424,0.000006425126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002321075,"about_ca_system_score_gemma":0.002587721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000015217,"about_ca_topic_score_gemma":0.00001236862,"domain_scores_codex":[0.9935606,0.0002787165,0.005109276,0.0003360962,0.0003457603,0.0003696266],"domain_scores_gemma":[0.9918866,0.002553839,0.004538354,0.0002608499,0.0004616337,0.0002987479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001900531,0.0002181107,0.0002567282,0.001531511,0.002180219,0.0001614281,0.000008793194,0.000001572925,4.076857e-7,0.00001562257,0.03029992,0.9634252],"study_design_scores_gemma":[0.01192955,0.009427892,0.001057286,0.002293872,0.001726623,0.0001050912,0.00001738729,0.000007366623,2.269416e-7,0.00008030343,0.9732125,0.0001418661],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001433612,0.9914524,0.0002596072,0.003366737,0.003218019,0.001386325,0.00003804416,0.00002753998,0.0001079895],"genre_scores_gemma":[0.000006808333,0.9845546,0.007122494,0.002072973,0.004131771,0.00008571205,0.00003445651,0.00009085203,0.001900339],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9632833,"threshold_uncertainty_score":0.9752595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2375949059476379,"score_gpt":0.5638737964619235,"score_spread":0.3262788905142856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}